

RYSTIGGO® (rozanolixizumab-noli)

Injection For Subcutaneous Use
140 mg/mL

Join us for an informative discussion about RYSTIGGO!

The first and only FDA-approved targeted treatment for adults with either anti-AChR Ab+ or anti-MuSK Ab+ generalized myasthenia gravis (gMG).¹

Ab+=antibody positive; AChR=acetylcholine receptor; MuSK=muscle-specific tyrosine kinase.

INDICATION

RYSTIGGO (rozanolixizumab-noli) is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

IMPORTANT SAFETY INFORMATION

RYSTIGGO is associated with important warnings and precautions, including increased risk of infection, drug-induced aseptic meningitis, and hypersensitivity reactions. The most common adverse reactions (≥10%) in patients with gMG are headache, infections, diarrhea, pyrexia, hypersensitivity reactions, and nausea.

Please see the representative in the booth for the full Prescribing Information and visit www.RystiggoHCP.com.

Reference: 1. RYSTIGGO [Prescribing Information]. Smyrna, GA: UCB, Inc.

RYSTIGGO® is a registered trademark of the UCB Group of Companies.
©2024 UCB, Inc., Smyrna, GA 30080. All rights reserved. US-RZ-2400287

Listen to our featured speaker discuss RYSTIGGO

**Suraj Muley, MD
FAAN, FACP**

Medical Director at the Bob Bové Neuroscience Institute at HonorHealth, Scottsdale, Arizona

Wednesday, October 16

2:40 PM ET

**Presentation Stage by UCB, Inc.
Exhibit Hall A - Presentation Stage B**



Inspired by **patients**.
Driven by **science**.

ZILBRYSQ® (zilucoplan) Injection

You're invited to an informative discussion about ZILBRYSQ!

The first and only self-administered complement C5 inhibitor for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive (Ab+).^{1,2}

C5= complement component 5.

IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors; ZILBRYSQ is a complement inhibitor. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. Complete or update meningococcal vaccination at least 2 weeks prior to administering the first dose of ZILBRYSQ, unless the risk of delaying therapy outweighs the risk of developing a meningococcal infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccinations in patients receiving a complement inhibitor. Persons receiving ZILBRYSQ are at increased risk for invasive disease caused by *N. meningitidis*, even if they develop antibodies following vaccination. Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected. ZILBRYSQ is available only through a restricted program called ZILBRYSQ REMS. ZILBRYSQ is contraindicated in patients with unresolved *Neisseria meningitidis* infection. Use caution when administering ZILBRYSQ to patients with any other systemic infection. Pancreatitis and pancreatic cysts have been reported in patients treated with ZILBRYSQ. Discontinue ZILBRYSQ in patients with suspected pancreatitis and initiate appropriate management until pancreatitis is ruled out or has resolved. The most common adverse reactions ($\geq 10\%$) were injection site reactions, upper respiratory tract infections, and diarrhea.

INDICATION

ZILBRYSQ (zilucoplan) is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

Please see the representative in the booth for the full Prescribing Information and visit www.ZilbrysqHCP.com.

References: 1. ZILBRYSQ [Prescribing Information]. Smyrna, GA: UCB, Inc. 2. Howard JF Jr, Bresch S, Genge A, et al; RAISE Study Team. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Neurol.* 2023;22(5):395-406. doi:10.1016/S1474-4422(23)00080-7

ZILBRYSQ® is a registered trademark of the UCB Group of Companies.

©2024 UCB, Inc., Smyrna, GA 30080. All rights reserved. US-RZ-2400287

Hear more about ZILBRYSQ from our featured speaker

**Joshua P.
Alpers, MD**

Director, UT Erlanger
Neuromuscular Medicine Clinic,
Electrodiagnostic Medicine

Wednesday, October 16

9:40 AM ET

**Presentation Stage by UCB, Inc.
Exhibit Hall A - Presentation
Stage B**



**Inspired by patients.
Driven by science.**